AngioDynamics Inc (ANGO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AngioDynamics Inc (ANGO) has a cash flow conversion efficiency ratio of -0.018x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.11 Million) by net assets ($173.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AngioDynamics Inc balance sheet quality to measure how much of total assets are equity-financed.
AngioDynamics Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how AngioDynamics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of AngioDynamics Inc to evaluate the quality of earnings relative to operating cash generation.
AngioDynamics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AngioDynamics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Univanich Palm Oil Public Company Limited
BK:UVAN
|
0.184x |
|
Shanghai Koal Software Co Ltd
SHG:603232
|
0.000x |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
-0.412x |
|
Hefei Taihe Optoelectronic
SHG:603656
|
0.052x |
|
Chengdu Zhimingda Electronics Co. Ltd. A
SHG:688636
|
-0.030x |
|
Hunan Chen Dian International Development Co Ltd
SHG:600969
|
0.108x |
|
Tengda Construction Group Co Ltd
SHG:600512
|
-0.002x |
|
Yingkou Fengguang Advanced Material Co.Ltd.
SHE:301100
|
N/A |
Annual Cash Flow Conversion Efficiency for AngioDynamics Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of AngioDynamics Inc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see how much is AngioDynamics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-05-31 | $182.97 Million | $-10.13 Million | -0.055x | +59.59% |
| 2024-05-31 | $205.59 Million | $-28.16 Million | -0.137x | -66527.12% |
| 2023-05-31 | $378.30 Million | $78.00K | 0.000x | +101.22% |
| 2022-05-31 | $424.49 Million | $-7.19 Million | -0.017x | -130.91% |
| 2021-05-31 | $439.46 Million | $24.09 Million | 0.055x | +271.73% |
| 2020-05-31 | $455.87 Million | $-14.55 Million | -0.032x | -152.43% |
| 2019-05-31 | $614.82 Million | $37.44 Million | 0.061x | -19.97% |
| 2018-05-31 | $542.60 Million | $41.29 Million | 0.076x | -29.43% |
| 2017-05-31 | $517.03 Million | $55.74 Million | 0.108x | +20.90% |
| 2016-05-31 | $507.03 Million | $45.22 Million | 0.089x | +89.23% |
| 2015-05-31 | $545.02 Million | $25.68 Million | 0.047x | +2.71% |
| 2014-05-31 | $537.89 Million | $24.68 Million | 0.046x | -9.30% |
| 2013-05-31 | $526.83 Million | $26.65 Million | 0.051x | +128.22% |
| 2012-05-31 | $523.39 Million | $11.60 Million | 0.022x | -73.44% |
| 2011-05-31 | $405.75 Million | $33.87 Million | 0.083x | -18.25% |
| 2010-05-31 | $391.35 Million | $39.96 Million | 0.102x | +90.57% |
| 2009-05-31 | $372.19 Million | $19.94 Million | 0.054x | -26.43% |
| 2008-05-31 | $355.71 Million | $25.91 Million | 0.073x | +178.55% |
| 2007-05-31 | $335.96 Million | $8.78 Million | 0.026x | +0.26% |
| 2006-05-31 | $123.44 Million | $3.22 Million | 0.026x | -73.25% |
| 2005-05-31 | $49.11 Million | $4.79 Million | 0.097x | +45.20% |
| 2004-05-31 | $37.23 Million | $2.50 Million | 0.067x | -85.31% |
| 2003-05-31 | $1.49 Million | $680.00K | 0.457x | +111.18% |
| 2002-05-31 | $-295.00K | $1.21 Million | -4.088x | -- |
About AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall … Read more